drugset
drugset / Trial / NCT00125190

Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency

NCT00125190 ↗

Phase 2/3 Completed 45 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

This study is intended to assess the effects of once daily dosing of recombinant human insulin-like growth factor (rhIGF-1) in increasing height velocity.

Timeline

Start
2005-07
Primary completion
2009-01
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject mecasermin Protein / enzyme biologic — Subcutaneous

Indications

growth delay due to insulin-like growth factor type 1 deficiency